Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study of IV Ravulizumab in Patients With COVID-19 Severe Pneumonia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Males or female participants ≥ 18 years of age and ≥ 40 kilograms at the time of providing informed consent.~2. Confirmed diagnosis of severe acute respiratory syndrome coronavirus 2 infection (for example, via polymerase chain reaction and/or antibody test) presenting as severe COVID-19 requiring hospitalization.~3. Severe pneumonia, acute lung injury, or acute respiratory distress syndrome confirmed by computed tomography or X-ray at Screening or within the 3 days prior to Screening, as part of the participant's routine clinical care.~4. Respiratory distress requiring mechanical ventilation, which can be either invasive (requiring endotracheal intubation) or noninvasive (with continuous positive airway pressure or bilevel positive airway pressure).~5. Female participants of childbearing potential and male participants with female partners of childbearing potential must follow protocol specified contraception guidance for avoiding pregnancy for 8 months after treatment with the study drug.~Exclusion Criteria:~1. Participant was not expected to survive for more than 24 hours.~2. Participant was on invasive mechanical ventilation with intubation for more than 48 hours prior to Screening.~3. Severe pre-existing cardiac disease (that is, New York Heart Association Class 3 or Class 4, acute coronary syndrome or persistent ventricular tachyarrhythmias).~4. Participant had an unresolved Neisseria meningitidis infection.~5. Used the following medications and therapies:~   * Current treatment with a complement inhibitor or~  * Intravenous immunoglobulin within 4 weeks prior to randomization on Day 1~6. Treatment with investigational therapy in a clinical study within 30 days before randomization, or within 5 half-lives of that investigational therapy, whichever was greater. Exceptions:~   * Investigational therapies were allowed if received as part of BSC through an expanded access protocol or emergency approval for the treatment of COVID-19.~  * Investigational antiviral therapies (such as remdesivir) were allowed even if received as part of a clinical study.~7. Female participants who were breastfeeding or who have a positive pregnancy test result at Screening.~8. History of hypersensitivity to any ingredient contained in the study drug, including hypersensitivity to murine proteins.~9. Participant who was not currently vaccinated against Neisseria meningitidis, unless the participant agrees to receive prophylactic treatment with appropriate antibiotics for at least 8 months after the last infusion of study drug or until at least 2 weeks after the participant receives vaccination against Neisseria meningitidis.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group 1 - Ravulizumab + BSC (Type: EXPERIMENTAL): None
- Group 2 - BSC alone (Type: OTHER): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy